Centre Henri Becquerel

The medical center is at the forefront of research in myelodysplastic syndromes and acute myeloid leukemia, focusing on innovative treatment combinations and therapeutic strategies for patients ineligible for traditional therapies.

• ONUREG and VENETOCLAX combination therapy
• RVU120 monotherapy and combination with Venetoclax
• ASTX727 and donor lymphocyte infusions post-transplant

These studies aim to improve survival rates and quality of life for patients with high-risk conditions, offering new hope through advanced therapeutic regimens.

Specializing in breast cancer research, the center explores cutting-edge treatments for various subtypes, including hormone receptor-positive and HER2-negative cancers.

• Durvalumab, Olaparib, and Fulvestrant combination
• Palbociclib and Fulvestrant for early detection of molecular relapse
• Capivasertib with CDK4/6 inhibitors and Fulvestrant

These trials focus on enhancing progression-free survival and tailoring therapies to genetic profiles, advancing personalized medicine in oncology.

The center is a leader in the study of lymphomas and other hematologic malignancies, developing novel therapies to improve patient outcomes.

• Glofitamab for relapsed/refractory lymphomas
• Polatuzumab Vedotin in combination with R-GEMOX
• BiCAR Therapy post-CAR T-cell treatment

Research efforts are directed towards increasing remission rates and reducing relapse through innovative drug combinations and targeted therapies.

Focusing on prostate cancer and lung cancer, the center conducts pivotal studies to enhance treatment efficacy and patient survival.

• Darolutamide with radiotherapy for high-risk prostate cancer
• 177Lu-PSMA-617 for metastatic hormone-sensitive prostate cancer
• Immunotherapy and local ablative treatments for NSCLC

These trials aim to refine therapeutic approaches, integrating advanced imaging and molecular diagnostics to optimize patient care.

In the realm of head and neck cancer, the center is pioneering studies that combine immunotherapy with traditional treatments to improve outcomes.

• Lenvatinib and Pembrolizumab combination therapy
• Dostarlimab as sequential therapy post-chemoradiation
• TPEx regimen with avelumab and cetuximab

Research is focused on enhancing overall survival and reducing recurrence through innovative treatment protocols.